**Paraneoplastic Glomerulopathy Associated with Renal Cell Carcinoma**

Akihiro Tojo

[23] Flanigan RC. The failure of infarction and/or nephrectomy in stage IV renal cell can‐ cer to influence survival or metastatic regression. *Urol Clin North Am* 1987;14:757–62.

[24] Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastases. *BJU Int*

[25] Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. *Urology*

[26] Bono AV, Caresano A. The role of embolization in the treatment of kidney carcino‐

[27] Parker S, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. *Cancer J Clin* 1996;46:5–

[28] Ridley SL, Culp SH, Jonascg F et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. *Ann*

[29] Mahnken AH, Rohde D, Brkovic D, Gunther RW, Tacke JA. Percutaneous radiofre‐ quency ablation of renal cell carcinoma – preliminary results. *Acta Radiol*

[30] Marberger M, Schatzl G, Cranston D, Kennedy JE. Extracorporeal ablation of renal tumours with high-intensity focused ultrasound*. BJU Int* 2005;95(Suppl. 2):52–5.

[31] Stenzel A, deKernion JB. Pathology, biology, and clinical staging of renal cell carcino‐

[32] Dąbrowski MP, Stankiewicz W, Płusa T, Chciałowski A, Szmigielski S. Competition of IL-1 and IL-1 ra determines lymphocyte response to delayed stimulation with

[33] Dąbrowski MP, Stankiewicz W. Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor. *J Chemotherapy*, 2001, 13, 1-6.

[34] Catalona WJ, Ratliff TL, McCool RE. Concanavalin A-activated suppressor cell activi‐ ty in peripheral blood lymphocytes of urologic cancer patients. *J Natl Cancer Inst.*

[35] Osada J, Pietruczuk M, Dabrowska M, Kordecki K, Janica J, Walecki J. An assessment of lymphocytic population in peripheral blood of patients with renal cell carcinoma before and after embolization [In Polish]. *Rocz Akad Med* Bialystok. 2000; 45: 228-39.

2001;87:312–5.

2000;55:36–40.

27.

108 Renal Tumor

ma. *Eur Urol* 1983;9:334–7.

*Oncol* 2011; 22: 1048-53

ma. *Sem Oncol (Suppl.)* 1989;16:3–11.

PHA. *Mediators of Inflammation*. 2001; 10, 101-7.

2005;46:208–14.

1980; 65: 553-7.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53534
